Peptide formulation development addresses the inherent challenges of peptide drugs: poor stability, low bioavailability, aggregation tendency, and immunogenicity. This guide covers the systematic approach from early-stage formulation to commercial product.
| Challenge | Cause | Solution |
|---|
| Chemical instability | Hydrolysis, oxidation, deamidation | pH optimization, antioxidants |
| Physical instability | Aggregation, fibrillation | Surfactants, co-solvents |
| Low bioavailability | GI degradation, poor permeability | Permeation enhancers, nanocarriers |
| Immunogenicity | T-cell epitopes, aggregates | Sequence modification, PEGylation |
| Short half-life | Renal clearance, enzymatic degradation | PEGylation, fatty acylation |
| Excipient | Function | Concentration | Notes |
|---|
| Sodium chloride | Tonicity adjuster | 0.4–0.9% | Most common |
| Mannitol | Tonicity, bulking | 2–5% | For lyophilization |
| Sucrose | Stabilizer, tonicity | 2–10% | Cryoprotectant |
| Trehalose | Stabilizer | 5–15% | Lyophilization excipient |
| Glycine | Bulking agent | 1–2% | Lyophilization |
| Polysorbate 80 | Surfactant | 0.01–0.1% | Prevents aggregation |
| Polysorbate 20 | Surfactant | 0.01–0.05% | Mild alternative |
| BSA/stabilizer protein | Competitor | 0.1–1 mg/mL | Research only |
| EDTA | Metal chelator | 0.05–0.5 mM | Prevents metal-catalyzed oxidation |
| L-methionine | Antioxidant | 0.1–0.5% | Prevents oxidation |
| Ascorbic acid | Antioxidant | 0.05–0.5% | pH-dependent |
- Optimal range: pH 4.0–7.0 for most peptides
- pH 4–5: Minimizes deamidation (Asn, Gln)
- pH 6–7: Minimizes acid hydrolysis (Asp-Pro)
- Buffer selection: Acetate (pH 4–5), phosphate (pH 6–8), histidine (pH 5–7)
Stability-indicating methods:
- HPLC purity at 25°C, 40°C/75% RH for 2 weeks
- Aggregation by SEC or DLS
- Potency by bioassay
High-throughput screening:
- 96-well plate formulation library
- Automated robotic liquid handling
- Quick stability assessment (1–2 weeks)
Typical lyophilization cycle:
| Phase | Temperature | Time | Shelf Position |
|---|
| Loading | 5°C | 30 min | 0% |
| Freezing | -45°C | 4 hr | -100%/hr |
| Annealing | -10°C | 2 hr | +200%/hr |
| Freezing | -45°C | 2 hr | -100%/hr |
| Primary drying | -30°C | 24–48 hr | +5%/hr |
| Secondary drying | 25°C | 6–12 hr | +20%/hr |
| Stoppering | 25°C | 5 min | Under N₂ |
| Parameter | Effect of Deviation |
|---|
| Freezing rate | Fast → small crystals, faster drying |
| Primary drying T | Too high → melt-back, collapse |
| Primary drying P | Too high → slow drying; too low → sublimation too fast |
| Secondary drying T | Too high → chemical degradation |
| Cake appearance | Uniform, white, no collapse, easy reconstitution |
| Parameter | Good | Acceptable | Poor |
|---|
| Appearance | Uniform, white | Slight discoloration | Collapse, melt-back |
| Reconstitution time | <30 sec | 30–60 sec | >60 sec |
| Residual moisture | <1% | 1–2% | >2% |
| Cake integrity | No cracks | Minor cracks | Severe cracking |
- Volume: 0.5–5 mL (SC), 1–100 mL (IV)
- Concentration: 5–100 mg/mL
- Container: Glass vials (Type I), pre-filled syringes, cartridges
- Stopper: Butyl rubber, fluoropolymer-lined
| System | Duration | Examples |
|---|
| Microspheres (PLGA) | 1–6 months | Lupron Depot, Risperdal Consta |
| In situ forming | 1–6 months | Eligard |
| Liposomes | Hours–days | Doxil |
| Nanoparticles | Hours–days | Abraxane |
- PEG size: 5–40 kDa (larger → longer half-life)
- Attachment: Lysine, N-terminal, Cys, or site-specific
- Examples: PEGylated interferon, PEG-asparaginase
| Enhancer | Mechanism | Concentration |
|---|
| SNAC | Transcellular absorption | 300–600 mg |
| Sodium caprate | Paracellular opening | 100–300 mg |
| Salcaprozate (SNAC) | Self-emulsifying | 300 mg |
| Bile salts | Micelle formation | 100–200 mg |
| Cell-penetrating peptides | Endocytosis | Variable |
- Protects from gastric acid and enzymes
- Materials: Eudragit L/S, HPMC-AS, shellac
- Release at pH > 5.5 (small intestine)
- Concentration: 10–50 mg/mL
- Volume: 25–200 µL per nostril
- pH: 4.5–6.5 (minimizes irritation)
- Tonicity: 280–320 mOsm/kg
- Viscosity: <5 cP for spray device
| Enhancer | Concentration | Enhancement |
|---|
| Chitosan | 0.25–1% | 2–10× |
| Bile salts | 0.5–2% | 5–20× |
| Cyclodextrins | 5–10% | 2–5× |
| EDTA | 0.1–0.5% | 2–5× |
- Particle size: 1–5 µm (MMAD)
- 载体: Lactose, mannitol
- Stabilizers: Trehalose, sucrose
- Examples: Exubera (insulin), Afrezza (insulin)
- Solution: Aqueous, pH 5–7
- Nebulizer type: Jet or vibrating mesh
- Output: 50–80% fine particle fraction
| Stress | Conditions | Products |
|---|
| Hydrolysis | 0.1 M HCl, 80°C, 24 hr | Deamidation, hydrolysis |
| Oxidation | 3% H₂O₂, 25°C, 24 hr | Met/Cys oxidation |
| Photolysis | ICH Q1B | Photo-oxidation |
| Thermal | 80°C, 24 hr | Aggregation, degradation |
| Method | Parameter | Sensitivity |
|---|
| RP-HPLC | Chemical purity | 0.1% impurity |
| SEC | Aggregation | 0.1% aggregate |
| DLS | Sub-visible particles | 10–1000 nm |
| MFI | Visible particles | 2–100 µm |
| iCIEF | Charge variants | 0.1% charge heterogeneity |
| Section | Content |
|---|
| Drug substance | Manufacturing process, specifications |
| Drug product | Formulation, manufacturing, specifications |
| Stability | ICH stability data |
| Comparability | Post-change bridging studies |
- FDA: Guidance for Industry on Peptide Drug Products
- EMA: Guideline on the chemistry, quality, and documentation of new active substances
- ICH Q6B: Specifications for biotechnological products
- Manning, M.C., et al. “Stability of protein pharmaceuticals.” Pharmaceutical Research 12 (1995): 473–482.
- Aso, N., et al. “Peptide formulation.” Advanced Drug Delivery Reviews 54 (2002): 787–802.
- Brown, L.R. “Commercial challenges of protein drug delivery.” Expert Opinion on Drug Delivery 1 (2004): 67–82.
